Semax Interactions: What the Literature Covers on Alcohol, Caffeine, Food and Other Compounds

What the Semax interaction literature actually contains

Semax is a synthetic peptide analogue of the ACTH(4-10) fragment, and N-acetyl Semax refers to a version carrying an acetyl group at the N-terminus. Most of the published record is single-agent work: cell models, rodent pharmacology, and reviews that place the peptide alongside other regulatory peptides. A 2025 bench study examined the effect of Semax on intracellular calcium dynamics in rat brain neurons, and researchers reported changes in calcium signalling in that preparation (PMID 41171324). A separate 2025 analysis looked at genes associated with the action of ACTH-like peptides with neuroprotective potential across rat brain regions with different degrees of ischaemic damage (PMID 40650034). Broader reviews discuss regulatory peptides within pharmacological aspects of neuro-immune interactions (PMID 28875850) and within therapeutic peptides in gerontology (PMID 42021992).

None of those papers was designed as an interaction study. That distinction matters for every question on this page: an interaction finding requires an experiment in which two agents were given together and compared against each alone. Where that design is absent, the only honest statement is that the pairing has not been studied in the literature summarised here.

How researchers separate two kinds of interaction question

Pharmacology distinguishes pharmacokinetic interactions, one substance changing the absorption, distribution, metabolism or elimination of another, from pharmacodynamic interactions, where two substances act on overlapping systems and their effects add, oppose or multiply. Peptide research raises a third consideration: peptidase degradation and route of delivery, since intranasal and parenteral routes bypass the gastrointestinal tract entirely. These frameworks are how investigators reason about untested pairings, but reasoning is not data, and the sections below flag which is which.

Semax and Alcohol: What Studies Report

No controlled study in this citation set administered ethanol together with Semax or N-acetyl Semax, in animals or in humans. There is therefore no published measurement of whether alcohol alters Semax exposure, whether Semax alters intoxication or withdrawal measures, or whether the combination produces effects absent from either alone.

Three strands of the published literature are commonly invoked when the question is raised, and each is mechanistic extrapolation rather than interaction evidence:

• Gastric mucosa. Alcohol is a well-known gastric irritant, and Semax has been studied in gastric contexts. A rat study examined the effect of Semax on homeostasis of the gastric mucosa in albino rats (PMID 11177268), and a 2002 report described therapy of peptic ulcer with Semax peptide (PMID 12459874). Neither study examined alcohol co-exposure, so these findings describe the peptide alone, not a combination.
• The corticotropin axis. Semax derives from an ACTH fragment, and work on synthetic and natural corticotropins has compared their individual activity (PMID 27921334). Because alcohol is known in general endocrinology to influence stress-axis signalling, some commentary reasons by analogy; the cited corticotropin paper did not test ethanol.
• Neuro-immune signalling. A review of pharmacological aspects of neuro-immune interactions situates regulatory peptides within immune-brain signalling (PMID 28875850), a system that general toxicology associates with chronic alcohol exposure, again, an analogy drawn across literatures rather than a measured interaction.

Researchers also note that a short peptide delivered intranasally is not expected to depend on the hepatic cytochrome pathways through which many small molecules interact with ethanol. That expectation is a prediction about pathways, not an observation from a co-administration experiment, and no paper in this set tested it.

Semax and Caffeine: What Studies Report

The verified literature contains no study in which caffeine and Semax were given together, and no published pharmacokinetic comparison of the peptide with and without caffeine. Nothing in this citation set supports a statement about additive, synergistic or opposing effects.

The mechanistic reasoning offered in commentary usually runs as follows, and is labelled here as extrapolation: caffeine is described in classical pharmacology as an adenosine receptor antagonist handled largely by hepatic metabolism, whereas Semax is a peptide studied for receptor-level and gene-expression effects in brain tissue, such as the gene associations reported across ischaemically damaged rat brain regions (PMID 40650034) and the neuronal calcium dynamics the 2025 study measured (PMID 41171324). Because those endpoints were measured without caffeine present, the experiments cannot say what a combination would do. Any claim that the two "stack" or "cancel out" is unsupported by the papers cited here.

Food, Fasting and Route of Administration

No fed-versus-fasted pharmacokinetic study of Semax appears in this citation set, and no paper reported that a meal, a fasting window or a particular macronutrient changed peptide exposure or effect size. The reason the question is usually framed differently for peptides is that the most commonly studied routes in this literature are not oral, so first-pass gastrointestinal exposure is not the main variable researchers model.

What the literature does contain is gastrointestinal pharmacology in its own right. The rat study on gastric mucosal homeostasis examined mucosal parameters directly (PMID 11177268), and the peptic ulcer report described Semax use in that clinical context (PMID 12459874). Those are findings about the digestive tract as a target, not about food timing as a modifier of peptide activity, a distinction frequently blurred in secondary summaries.

Semax and Other Compounds

Fluvoxamine and serotonergic drugs

The nearest thing to a published combination experiment in this set is a rat study in which researchers examined Semax, a synthetic ACTH(4-10) analogue, against behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats; the study reported that Semax attenuated those alterations (PMID 33418449). That design tested a peptide given in the context of prior exposure to a selective serotonin reuptake inhibitor in a developmental rodent model. It is not a human co-administration trial, it does not describe concurrent dosing in adults, and it does not generalise to other antidepressants.

Copper, zinc and other metal ions

Metal coordination is one of the few areas where the chemistry of combination has been measured directly. A 2016 study examined how N-terminus acetylation of Semax influenced copper(II) and zinc(II) coordination and biological properties (PMID 27586814), which is directly relevant to the acetylated form of the peptide. A 2022 study reported that Semax affected copper-induced amyloid-beta aggregation and amyloid formation in artificial membrane models (PMID 35080861). Related methodological work described a high-efficiency microarray strategy for discovering full-length amyloid-beta peptide ligands (PMID 29234579). These are chemistry and model-membrane experiments; none of them measured what happens when a person consuming a zinc or copper supplement also receives the peptide, and the authors did not frame them as dietary interaction studies.

Other neuroprotective agents and in-silico comparisons

Comparative pharmacology in this field sometimes uses computational profiling rather than co-administration. A comparative chemoreactome analysis of mexidol illustrates that approach, modelling a molecule's predicted interaction profile computationally (PMID 28514338). Chemoreactome output is a prediction generated from chemical structure and reference databases; it is not a clinical or animal combination result, and it should not be read as evidence that any two agents were tested together.

Corticotropins and ACTH-related compounds

Because Semax is an ACTH fragment analogue, questions about overlap with corticotropin preparations recur. Work comparing synthetic and natural corticotropins examined their individual activity (PMID 27921334), and the ACTH-like peptide gene-expression analysis characterised peptide action across rat brain regions (PMID 40650034). Neither study paired Semax with a corticotropin drug to measure a combined effect.

Evidence status at a glance

Combination-Related Adverse Events: What Studies Report

Within this citation set, no paper reported adverse events arising specifically from combining Semax with alcohol, caffeine, food, supplements or another drug, because no paper tested those combinations in a design capable of detecting them. The rat study involving early-life fluvoxamine exposure reported behavioural and neurochemical outcomes in that model rather than a human tolerability profile (PMID 33418449), and the laboratory metal-binding work reported chemical and biological properties of the acetylated peptide rather than clinical events (PMID 27586814). Reviews that place peptides in neuro-immune (PMID 28875850) and gerontological (PMID 42021992) frameworks summarise mechanisms rather than catalogue combination safety data. Absence of reported events in studies that did not look for them is not the same as evidence of absence.

Limitations readers should keep in view

• Most findings here come from rodents, isolated neurons, artificial membranes or computational models, and species and model differences limit translation (PMID 41171324).
• Mechanistic plausibility, including arguments about peptidase degradation or hepatic metabolism, generates hypotheses, not interaction conclusions.
• Secondary summaries sometimes convert a single-agent finding, such as the gastric mucosal work in rats (PMID 11177268), into a combination claim; the original reports do not support that step.
• Regulatory status differs by country, and research-use-only materials are not equivalent to approved medicines.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, supplement, substance or health condition. It describes what published studies examined and reported, and it does not recommend, endorse or discourage any combination.

References

• Pharmacological Aspects of Neuro-Immune Interactions (Current pharmaceutical design, 2018)
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in aging, 2026)
• The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons (Bulletin of experimental biology and medicine, 2025)
• Synacton and individual activity of synthetic and natural corticotropins (Journal of molecular recognition : JMR, 2017)
• Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage (International journal of molecular sciences, 2025)
• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (Neuropeptides, 2021)
• Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models (ACS chemical neuroscience, 2022)
• [A comparative chemoreactome analysis of mexidol] (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2017)
• Strategy to discover full-length amyloid-beta peptide ligands using high-efficiency microarray technology (Beilstein journal of nanotechnology, 2017)
• Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties (Journal of inorganic biochemistry, 2016)
• Therapy of peptic ulcer with semax peptide (Bulletin of experimental biology and medicine, 2002)
• Effect of Semax on homeostasis of gastric mucosa in albino rats (Bulletin of experimental biology and medicine, 2000)